Stratagene's Pact with Bayer Remains on Track, But Focus Alliance Hits a Snag After Quest Buy | GenomeWeb
Stratagene officials said this week that the firm’s collaboration with Bayer is on track, but its partnership with Focus Diagnostics has been disrupted by that firm being acquired by Quest Diagnostics earlier this year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.